Global Product Lead
CSL
University of Pittsburgh School of Medicine
King of Prussia, Pennsylvania, United States
Dr. Gregory Kato is Executive Director and Global Product Lead, Hematology Therapeutic Area at CSL Behring in King of Prussia, PA. He is a hematologist with particular expertise in sickle cell disease and other diseases affected by breakdown of red blood cells. He leverages his expertise, passion and network to find new ways to treat disease at plasma protein industry leader CSL Behring. He has nearly 30 years’ experience in patient care, consultative hematology, molecular biology lab and clinical trial research at Johns Hopkins, NIH and the University of Pittsburgh School of Medicine, where he was a tenured Professor of Medicine. He has authored over 200 research articles, review articles and book chapters, most on sickle cell disease. He is co-editor of the latest textbook on sickle cell disease. At CSL Behring, he is committed to full-time drug development in sickle cell disease and other hematology disorders. He connects the dots with a highly collaborative and integrative approach to problems. His goal is to put breakthrough treatment options in the hands of patients and prescribers for sickle cell disease and other blood diseases.
Disclosure information not submitted.
Investigational New Drug, Device, and Therapeutics Symposium
Friday, June 7, 2024
4:00 PM – 5:30 PM ET
CSL889 (Hemopexin) and Vamifeport as Potential Therapeutics for Sickle Cell Disease
Friday, June 7, 2024
4:20 PM – 4:35 PM ET
Phase 1 Study of the Safety and Pharmacokinetics of CSL889 (Hemopexin) in Adults with SCD
Saturday, June 8, 2024
9:00 AM – 9:15 AM ET